Adenosine A2A receptor antagonists and Parkinson's disease: state of the art and future directions
- PMID:18537671
- DOI: 10.2174/138161208784480072
Adenosine A2A receptor antagonists and Parkinson's disease: state of the art and future directions
Abstract
Adenosine A(2A) receptors present in the central nervous system have been implicated in the modulation of motor functions. Accordingly, adenosine A(2A) receptor antagonists currently constitute an attractive non-dopaminergic option for use in the treatment of Parkinson's disease (PD). The highly enriched distributions of adenosine A(2A) receptors in striatopallidal neurons, and their ability to form functional heteromeric complexes with dopamine D(2) and metabotropic glutamate mGlu5 receptors, render A(2A) receptor antagonists of particular interest in the modulation of motor behavior, whilst at the same time displaying a low predisposition to inducing non-motor side effects. Furthermore, adenosine A(2A) receptor antagonists appear to exert a marked efficacy on PD tremor and in reducing the progress of underlying neurodegeneration and maladaptive neuroplasticity that complicates standard dopamine replacement treatments in PD. Finally, recent evidence has illustrated an improvement of cognitive function as well as enhancement of attention in rodents following administration of A(2A) receptor antagonists. This article is aimed at examining preclinical studies describing these findings as well as reports from clinical trials, in order to provide a comprehensive review of the evidence suggesting that this class of drugs may represent an advance in the treatment of PD.
Similar articles
- Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications.Morelli M, Di Paolo T, Wardas J, Calon F, Xiao D, Schwarzschild MA.Morelli M, et al.Prog Neurobiol. 2007 Dec;83(5):293-309. doi: 10.1016/j.pneurobio.2007.07.001. Epub 2007 Jul 27.Prog Neurobiol. 2007.PMID:17826884Review.
- Targeting adenosine A2A receptors in Parkinson's disease.Schwarzschild MA, Agnati L, Fuxe K, Chen JF, Morelli M.Schwarzschild MA, et al.Trends Neurosci. 2006 Nov;29(11):647-54. doi: 10.1016/j.tins.2006.09.004. Epub 2006 Oct 9.Trends Neurosci. 2006.PMID:17030429Review.
- Interaction of adenosine receptors with other receptors from therapeutic perspective in Parkinson's disease.Morin N, Di Paolo T.Morin N, et al.Int Rev Neurobiol. 2014;119:151-67. doi: 10.1016/B978-0-12-801022-8.00007-6.Int Rev Neurobiol. 2014.PMID:25175965
- Pharmacological interactions between adenosine A2A receptor antagonists and different neurotransmitter systems.Pinna A, Serra M, Marongiu J, Morelli M.Pinna A, et al.Parkinsonism Relat Disord. 2020 Nov;80 Suppl 1:S37-S44. doi: 10.1016/j.parkreldis.2020.10.023. Epub 2020 Dec 19.Parkinsonism Relat Disord. 2020.PMID:33349579Review.
- Adenosine, adenosine A 2A antagonists, and Parkinson's disease.Jenner P, Mori A, Hauser R, Morelli M, Fredholm BB, Chen JF.Jenner P, et al.Parkinsonism Relat Disord. 2009 Jul;15(6):406-13. doi: 10.1016/j.parkreldis.2008.12.006. Epub 2009 May 15.Parkinsonism Relat Disord. 2009.PMID:19446490Review.
Cited by
- Clinical applications involving CNS gene transfer.Kantor B, McCown T, Leone P, Gray SJ.Kantor B, et al.Adv Genet. 2014;87:71-124. doi: 10.1016/B978-0-12-800149-3.00002-0.Adv Genet. 2014.PMID:25311921Free PMC article.Review.
- How Are Adenosine and Adenosine A2A Receptors Involved in the Pathophysiology of Amyotrophic Lateral Sclerosis?Mori A, Cross B, Uchida S, Kerrick Walker J, Ristuccia R.Mori A, et al.Biomedicines. 2021 Aug 17;9(8):1027. doi: 10.3390/biomedicines9081027.Biomedicines. 2021.PMID:34440231Free PMC article.Review.
- Gene therapy in Parkinson's disease: rationale and current status.Feng LR, Maguire-Zeiss KA.Feng LR, et al.CNS Drugs. 2010 Mar;24(3):177-92. doi: 10.2165/11533740-000000000-00000.CNS Drugs. 2010.PMID:20155994Free PMC article.Review.
- 2016 Philip S. Portoghese Medicinal Chemistry Lectureship: Designing Bivalent or Bitopic Molecules for G-Protein Coupled Receptors. The Whole Is Greater Than the Sum of Its Parts.Newman AH, Battiti FO, Bonifazi A.Newman AH, et al.J Med Chem. 2020 Mar 12;63(5):1779-1797. doi: 10.1021/acs.jmedchem.9b01105. Epub 2019 Sep 24.J Med Chem. 2020.PMID:31499001Free PMC article.
- Endocannabinoid signaling mediates psychomotor activation by adenosine A2A antagonists.Lerner TN, Horne EA, Stella N, Kreitzer AC.Lerner TN, et al.J Neurosci. 2010 Feb 10;30(6):2160-4. doi: 10.1523/JNEUROSCI.5844-09.2010.J Neurosci. 2010.PMID:20147543Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical